There is no doubt that we are living in unprecedented times, and this calls for an unprecedented response from everyone. The scientific community has joined efforts to collect knowledge and push the therapeutic response to Covid-19, the disease associated with the new strain of coronavirus, as fast as possible. New collaborations are being born every day and scientific data are shared widely as soon as they become available. With this editorial we not only wish to discuss the challenges that the scientific community and the publishing world are facing but also would like to offer some word of advice for scientists preparing scientific articles, reviews, or opinion pieces on Covid-19.

iScience is an interdisciplinary journal that encourages collaborations among scientists and the cross-pollination of ideas. We publish primary research articles as well as reviews and perspective pieces. Our articles are published open access and therefore readily available to the broad scientific community and the general public; however, iScience is also joining forces with all other Cell Press journals by contributing to the [resource center](https://www.cell.com/2019-nCOV){#intref0010} where all relevant papers published by Cell Press are freely available for the duration of the outbreak.

Since the first case of transmission person-to-person was reported in China at the end of January, thousands of research articles, comments, editorials, and opinion pieces have been published. The scientific content evolved from the reports of the first clinical observations in Covid-19 patients to potential therapies and, more recently, to studies characterizing more closely the mechanism of action of the virus from its tropism, its replication kinetics, and the cell damage profiles, with implications for its clinical manifestations and transmissibility.

The focus of the scientific community is currently divided between finding strategies for detecting the virus (both currently infected cases and people who had the virus), alleviating the symptoms of the disease caused by the virus, and producing a viable vaccine. This will be the ultimate marathon whereby thousands of laboratories will cross the starting line but only a few will make the final leg. On the 23^rd^ of April, the first volunteers were injected with the Covid-19 vaccine, officially starting the vaccine human trial stage in the United Kingdom. Up to 1,102 participants will be recruited across multiple sites, and they will be divided into two groups, one receiving the new vaccine and one receiving a control vaccine. This means that we could have answers in a range of 2 to 6 months, depending on how fast the virus is spreading within the communities analyzed. The Department of Health and Social Care in the United Kingdom has declared on the 29^th^ of April that Covid-19 treatments could be fast-tracked through a new national clinical trial initiative made possible by government, academia, and industry working together. Similar efforts are ongoing worldwide where several treatments are entering phase II and III clinical trials, and industries are working on ways to upscale vaccine production, keeping costs and timeline contained.

Our core role as Editors is to select the scientific content that is published by coordinating a thorough and timely peer review process. At iScience we are committed to helping authors through a no-nonsense approach. We try to minimize the number of peer review rounds a manuscript needs to go through and we make an extra effort in assisting authors navigating reports with the help of our reviewers and Advisory Editorial Board. We focus more on what is required to support the conclusions proposed and less on what would be a nice addition or extension of the work presented. **However, we must stress that we will not choose speed over quality.**

The interdisciplinary nature of iScience and the scarcity of experimental information on this new viral strain (especially now that so many laboratories are shut down) means that most research articles related to Covid-19 submitted to iScience are based on computational modeling and *in silico* experiments. iScience is proud to offer a venue where computational biologists and basic and translational researchers can meet and exchange information. However, we have seen a number of these studies failing in peer review. Below we report a few points that we believe will help speeding up the peer review process:-A thorough description of the computational modeling, or the experimental details of the *in silico* experiments, must be duly reported. This is key for the reviewers to judge the solidity of the study, and we will be requesting this before peer review.-The predictions made by the computational modeling should be validated in some shape or form. If this is not possible experimentally, a computational validation should be provided at the very least. In absence of any validation, we will not consider the manuscript for peer review.-The codes must be available for reviewers and for the scientific community when the manuscript is published. Now more than ever, reproducibility and transparency of reporting is key and we, as editors, will be mandating this on the get go.-For therapeutically relevant findings, the use of human cell lines represents a minimum requirement for the manuscripts to be sent out for peer review.

iScience publishes findings that constitute an advance in a specific filed; although we are open to replication studies, they must bring value (as a resource or providing a novel perspective) to the community.

We have also seen an increase in submissions of reviews and opinion pieces (which we publish under the perspective format). Our editorial advice in this case is to make sure that the authors are offering something that has not been discussed already or, at the very least, are providing a different perspective. It is easy to be extremely speculative at this stage, and we warn authors to make sure that the opinion they are putting forward is supported by scientific observations that have been published in peer-reviewed journals. A second piece of advice to avoid disappointment when writing an opinion piece is to make sure that the discussion is developed at an academic level and that the author possesses adequate competences to fully eviscerate the implications of the topic under discussion.

We hope our authors, reviewers, and readers will appreciate the efforts we are putting in to help reach a resolution to this global pandemic. We appreciate, now more than ever, the time and dedication our reviewers contribute to this effort.
